Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul-Aug;76(4):361-364.
doi: 10.1016/j.therap.2020.12.015. Epub 2020 Dec 26.

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19

Chia Siang Kow  1 , Syed Shahzad Hasan  2
Affiliations
Comment

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19

Chia Siang Kow et al. Therapie. 2021 Jul-Aug.
No abstract available

Keywords: Covid-19; DPP-4 inhibitors; Mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pooled odds for a fatal or severe course of illness in COVID-19 patients with preadmission use of DPP-4 inhibitors relative to non-use of DPP-4 inhibitors. (heterogeneity: I2 = 54%; P = 0.04). CI: confidence interval; DPP-4: dipeptidyl peptidase-4; OR: odds ratio.
See this image and copyright information in PMC

Comment in

Comment on

  • Diabetes and COVID-19.
    Bouhanick B, Cracowski JL, Faillie JL; French Society of Pharmacology, Therapeutics (SFPT). Bouhanick B, et al. Therapie. 2020 Jul-Aug;75(4):327-333. doi: 10.1016/j.therap.2020.05.006. Epub 2020 May 15. Therapie. 2020. PMID: 32425249 Free PMC article. Review.

References

    1. Bouhanick B., Cracowski J.L., Faillie J.L. French Society of Pharmacology, Therapeutics (SFPT). Diabetes and COVID-19. Therapie. 2020;75(4):327–333. - PMC - PubMed
    1. Chen Y., Yang D., Cheng B., Chen J., Peng A., Yang C. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43(7):1399–1407. - PubMed
    1. Kim M.K., Jeon J.H., Kim S.W., Moon J.S., Cho N.H., Han E., et al. The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea. Diabetes Metab J. 2020;44(4):602–613. - PMC - PubMed
    1. Rhee S.Y., Lee J., Nam H., Kyoung D., Kim D.J. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. Preprint. medRxiv. 2020 [2020.05.20.20108555] - PMC - PubMed
    1. Dalan R., Ang L.W., Tan W.Y.T., Fong S.W., Tay W.C., Chan Y.H., et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2020 [pvaa098] - PMC - PubMed

Substances